Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

F. Schettini, M. Giuliano, M. Lambertini, R. Bartsch, D.J. Pinato, C.E. Onesti, N. Harbeck, D. Luftner, S. Rottey, P.A. van Dam, K. Zaman, G. Mustacchi, J. Gligorov, A. Awada, M. Campone, H. Wildiers, A. Gennari, V.C.G. Tjan-Heijnen, J. Cortes, M. LocciI. Paris, L. Del Mastro, S. De Placido, M. Martin, G. Jerusalem, S. Venturini, G. Curigliano, D. Generali*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article number4421
Number of pages17
JournalCancers
Volume13
Issue number17
DOIs
Publication statusPublished - 1 Sep 2021

Keywords

  • anthracyclines
  • breast cancer
  • triple negative
  • hormone receptor
  • metastatic
  • non-pegylated liposomal doxorubicin
  • PHASE-III TRIAL
  • TRASTUZUMAB PLUS DOCETAXEL
  • ENCAPSULATED DOXORUBICIN
  • 1ST-LINE THERAPY
  • NAB-PACLITAXEL
  • CONVENTIONAL DOXORUBICIN
  • PRIMARY CHEMOTHERAPY
  • MULTICENTER TRIAL
  • CYCLOPHOSPHAMIDE
  • EPIRUBICIN

Cite this